Page 293 - TBE_Book_V2_2019

Chapter 12b: TBE in France

Table 2: TBE reporting and vaccine prevention in France
Mandatory TBE
No mandatory reporting in France in 2016, but in project for 2017
reporting
Laboratory reporting from positive serology testing

With national public health organisation (Santé Publique France) with the
collaboration of:
 the Arbovirus reference center, institut de recherche biomedicale des
armées (irba), hôpital d’instruction des armées Laveran – service de
biologie, Marseille and
 the Institut de Virologie, Hôpitaux Universitaires de Strabsourg, Strasbourg

Confirmed case definition: Clinical picture of acute TBE with CNS symptoms
(such as meningitis, encephalitis, myelitis)

Other TBE AND
surveillance
Positive findings with at least one of the following methods :
• Direct detection of virus
• Nucleic acid detection (e.g. PCR)
• IgM and IgG antibody detection in blood
 IgM antibody detection in CSF
• Four-fold rising of antibody titer or seroconversion in two successive
samples

Probable case definition
The same clinical definition as confirmed cases but with isolated IgM antibody
in blood.
Special clinical Approximately 50% of biphasic disease
features 1% mortality
Available vaccines Ticovac and Encepur
Vaccination
recommendtions Recommendations only for travelers going to endemic areas

and No reimbursement
reimbursement
Vaccine uptake by
age group/risk
No information available
group/general
population

Arbovirus Reference Center, Institut de Recherche Biomedicale des Armées
(Irba),
Name, address/ Hôpital d’Instruction des Armées Laveran – Service de Biologie
website of TBE NRC BP 60149 13384 MARSEILLE CEDEX 13
Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, 3, rue
Koeberlé, 67000 Strasbourg

288